# Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer

> **NCT01497925** · PHASE1 · COMPLETED · sponsor: **Polaris Group** · enrollment: 43 (actual)

## Conditions studied

- Solid Tumors
- Prostate Cancer

## Interventions

- **DRUG:** ADI-PEG 20

## Key facts

- **NCT ID:** NCT01497925
- **Lead sponsor:** Polaris Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09-06
- **Primary completion:** 2016-03-23
- **Final completion:** 2018-08-31
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2018-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01497925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01497925, "Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01497925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*